ABIONYX Pharma Provides an Update on Its Business and Cash Position for the First Half Of 2022

Continued focus of the Services activity on the Biotech's preclinical studies in ophthalmology Determination of the strategic axes of clinical development in ophthalmology is ongoing

Related Keywords

Paris ,France General ,France ,Arthur Rouill ,Nicolas Fossiez ,Louis Victor Delouvrier ,Research Tax Credit ,University Of Bari ,Compassionate Access Authorization ,Victor Delouvrier ,Abionyx ,Dharma ,Rovides ,Update ,Business ,Cash ,Position ,First ,Calf ,022 ,